Moraxella osloensis, an emerging pathogen of endocarditis in immunocompromised patients?

Jean-Charles Gagnard; Nadia Hidri; Antoine Grillon; Laurence Jesel; Eric Denes

doi:10.4414/smw.2015.14185

Peer reviewed clinical letter

Vol. 145 No. 3738 (2015)

Moraxella osloensis, an emerging pathogen of endocarditis in immunocompromised patients?

Jean-Charles Gagnard
Nadia Hidri
Antoine Grillon
Laurence Jesel
Eric Denes

DOI: https://doi.org/10.4414/smw.2015.14185
Cite this as:: Swiss Med Wkly. 2015;145:w14185
Published: 06.09.2015

Summary

We report two cases of endocarditis due to Moraxella osloensis. Only one previous case of such infection has been described. These infections occurred in immunocompromised patients (B-cell chronic lymphocytic leukaemia and kidney graft associated with Hodgkin’s disease) and both patients had a favourable outcome with a complete cure of their infectious endocarditis. This bacterium could be an emerging pathogen revealed by MALDI-TOF. Indeed, its characterisation within the Moraxella group by use of biochemistry-based methods is difficult. Moreover, this strain could be particularly involved in immunocompromised patients.

References

Murphy T. Moraxella (Branhamella) catarrhalis and other Gram-negative Cocci. Principles and Practice of Infectious Diseases. 2005. p. 2529–36.
Baumann P, Doudoroff M, Stanier RY. Study of the Moraxella group. I. Genus Moraxella and the Neisseria catarrhalis group. J Bacteriol. 1968;95(1):58–73.
Stryker TD, Stone WJ, Savage AM. Renal failure secondary to Moraxella osloensis endocarditis. Johns Hopkins Med J. 1982;150(6):217–9.
Bövre K, Henriksen SD. A new Moraxella species, Moraxella osloensis, and a nonliquefaciens, revised description of Moraxella. Intern J Syst Bacteriol. 1967;17:127–35.
Dien Bard J, Lewinski M, Summanen PH, Deville JG. Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child. J Med Microbiol. 2011;60:138–41.
Han XY, Tarrand JJ. Moraxella osloensis blood and catheter infections during anticancer chemotherapy: clinical and microbiologic studies of 10 cases. Am J Clin Pathol. 2004;121(4):581–7.

How to Cite

1.

Gagnard J-C, Hidri N, Grillon A, Jesel L, Denes E. Moraxella osloensis, an emerging pathogen of endocarditis in immunocompromised patients?. Swiss Med Wkly [Internet]. 2015 Sep. 6 [cited 2024 Nov. 28];145(3738):w14185. Available from: https://smw.ch/index.php/smw/article/view/2075

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

[1] Murphy T. Moraxella (Branhamella) catarrhalis and other Gram-negative Cocci. Principles and Practice of Infectious Diseases. 2005. p. 2529–36.

[2] Baumann P, Doudoroff M, Stanier RY. Study of the Moraxella group. I. Genus Moraxella and the Neisseria catarrhalis group. J Bacteriol. 1968;95(1):58–73.

[3] Stryker TD, Stone WJ, Savage AM. Renal failure secondary to Moraxella osloensis endocarditis. Johns Hopkins Med J. 1982;150(6):217–9.

[4] Bövre K, Henriksen SD. A new Moraxella species, Moraxella osloensis, and a nonliquefaciens, revised description of Moraxella. Intern J Syst Bacteriol. 1967;17:127–35.

[5] Dien Bard J, Lewinski M, Summanen PH, Deville JG. Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child. J Med Microbiol. 2011;60:138–41.

[6] Han XY, Tarrand JJ. Moraxella osloensis blood and catheter infections during anticancer chemotherapy: clinical and microbiologic studies of 10 cases. Am J Clin Pathol. 2004;121(4):581–7.